Vonoprazan: A New Oral P-CAB

Vonoprazan (trade name Takecab) is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.
Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
We manufacture and furnish high quality Vonoprazan impurities for global markets. More information is available on the official website: https://www.ex-biotech.com. If you have any questions, please send an email to sale@ex-biotech.com. We are looking forward to cooperating with you.